SuperworthEledon Pharmaceuticals shares outstanding ELDN
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2026
- 113.6M
- On a year earlier
- +47.3%
- more shares
Eledon Pharmaceuticals had 113.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 47.3% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 95.8M | +37% |
| FY2024 | 69.7M | +132% |
| FY2023 | 30M | +110% |
| FY2022 | 14.3M | −4% |
| FY2021 | 14.8M | +433% |
| FY2020 | 2.8M | +285% |
| FY2019 | 721.8K | +38% |
| FY2018 | 523.5K | +32% |
| FY2017 | 397.1K | +184% |
| FY2016 | 139.8K | +0% |
| FY2015 | 139.4K | +4479% |
| FY2013 | 3K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 113.6M | +47% | |
| Q1 FY26 | 112.4M | +46% | |
| Q4 FY25 | 95.8M | +37% | |
| Q3 FY25 | 77.2M | +39% | |
| Q2 FY25 | 77.2M | +82% | |
| Q1 FY25 | 77.1M | +157% | |
| Q4 FY24 | 69.7M | +132% | |
| Q3 FY24 | 55.5M | +85% | |
| Q2 FY24 | 42.3M | +76% | |
| Q1 FY24 | 30M | +110% | |
| Q4 FY23 | 30M | +110% | |
| Q3 FY23 | 30M | +110% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Eledon Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.